Clinical pharmacology of anti-angiogenic drugs in oncology

Abstract : Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate –pocket of different kinases. They have become an important part of some tumors' treatment, both in monotherapy or in combination. In this review, we discuss the key pharmacological concepts and the major pitfalls of anti-angiogenic prescriptions. We also review the pharmacokinetic and pharmacody-namics profile of all approved anti-angiogenic protein kinase inhibitors and the potential role of surrogate markers and of therapeutic drug monitoring.
Type de document :
Article dans une revue
Critical Reviews in Oncology/Hematology, Elsevier, 2017, 119, pp.75-93. 〈10.1016/j.critrevonc.2017.08.010〉
Liste complète des métadonnées

Littérature citée [206 références]  Voir  Masquer  Télécharger

http://hal.upmc.fr/hal-01662030
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : mardi 12 décembre 2017 - 16:04:05
Dernière modification le : mercredi 21 mars 2018 - 18:57:57

Fichier

Pharmacology of AA - 2017_sans...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

P. Gougis, J. Wassermann, J.P. Spano, N. Keynan, C. Funck-Brentano, et al.. Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, Elsevier, 2017, 119, pp.75-93. 〈10.1016/j.critrevonc.2017.08.010〉. 〈hal-01662030〉

Partager

Métriques

Consultations de la notice

47

Téléchargements de fichiers

2